SCHEMBL4779005

SCHEMBL4779005

CCOCCS(=O)(=O)c1ccc(CC2CCN(C(C)=O)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
CNR2 P34972 2/20 0.47
L3MBTL1 Q9Y468 3/20 0.46
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HTT P42858 2/20 0.40
DUSP3 P51452 1/20 0.40
PTPN5 P54829 1/20 0.40
PTPN11 Q06124 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770056 0.87 SMN1; SMN2 (0.52) ALDH1A1CNR2L3MBTL1CA12CA1
SCHEMBL4771675 0.85 CNR2 (0.51) ALDH1A1CNR2L3MBTL1CA12CA1
SCHEMBL4775690 0.84 SMN1; SMN2 (0.47) ALDH1A1CNR2L3MBTL1CA12CA1
SCHEMBL7513018 0.82 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4775645 0.81 GBA1 (0.44) ALDH1A1
SCHEMBL4768622 0.79 ALDH1A1 (0.53) ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3026497 0.79 CCR5 (0.55) ALDH1A1L3MBTL1CA12CA1CA2
SCHEMBL4771790 0.78 CA12 (0.46) ALDH1A1L3MBTL1CA12CA1CA2
SCHEMBL3040126 0.77 CA12 (0.50) ALDH1A1L3MBTL1CA12CA1CA2
SCHEMBL4777747 0.77 CA2 (0.67) ALDH1A1L3MBTL1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 ALDH1A1 3228/4885CNR2 79/4885L3MBTL1 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.